HURA - NASDAQ

TuHURA Biosciences, Inc.

HURA·NASDAQ

$2.19

+5.8%

HealthcareBiotechnology

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$139.46M

EPS-0.6300

P/E Ratio-3.48

Earnings Date08/13/2026

hura

Total Non-Current Liabilities

Last Annual Value

501.55K

3-Year CAGR

189%

5-Year CAGR

22%

10-Year CAGR

-5%

Adjust for Inflation

TuHURA Biosciences, Inc. Competitors Analysis of Total Non-Current Liabilities

HURA · NASDAQ

Company	Total Non-Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
TuHURA Biosciences, Inc. NASDAQ:HURA	501.55K	-40.0%	N/A	33.4%
Cognition Therapeutics, Inc. NASDAQ:CGTX	195.00K	-27.9%	N/A	N/A
Seer, Inc. NASDAQ:SEER	21.09M	-6.9%	-1.6%	N/A
Context Therapeutics Inc. NASDAQ:CNTX	0.00	N/A	N/A	N/A
Ovid Therapeutics Inc. NASDAQ:OVID	11.99M	-35.5%	N/A	N/A
Armata Pharmaceuticals, Inc. AMEX:ARMP	286.53M	36.0%	48.6%	50.2%
Inovio Pharmaceuticals, Inc. NASDAQ:INO	6.55M	-16.0%	-26.5%	0.1%
Seres Therapeutics, Inc. NASDAQ:MCRB	74.65M	-37.4%	-12.0%	-3.8%
Agenus Inc. NASDAQ:AGEN	181.17M	-4.3%	-7.0%	1.6%
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS	22.40M	-9.5%	N/A	N/A
VistaGen Therapeutics, Inc. NASDAQ:VTGN	1.34M	-32.9%	-35.6%	-4.7%

TuHURA Biosciences, Inc. Fair Value Envelope

HURA · NASDAQ

Our analysis suggests that HURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.19, this represents a potential HIDDEN relative to our calculated worth for TuHURA Biosciences, Inc..

HIDDEN

Intrinsic Value

Current Price: $2.19

Related Guides

Blog Categories

Continue your HURA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.